Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-21), Vext Science's 9-Day RSI is 57.09.
The industry rank for Vext Science's 9-Day RSI or its related term are showing as below:
FRA:VV5's 9-Day RSI is ranked worse than 88.13% of 1045
companies
in the Drug Manufacturers industry
Industry Median: 47.8
vs FRA:VV5: 57.09
Vext Science (FRA:VV5) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Vext Science 9-Day RSI Related Terms
FRA:VV5 vs ZTS, UTHR: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vext Science 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vext Science's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Vext Science's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vext Science (FRA:VV5) has a 9-Day RSI of 57.09 as of Jul. 21, 2026. According to the industry distribution chart, Vext Science ranks #921 out of 1045 companies in the Drug Manufacturers industry, placing it in the top 88.1%.
Is Vext Science's 9-Day RSI too high?
Vext Science's current 9-Day RSI is 57.09. The Drug Manufacturers industry median 9-Day RSI is 47.80. Vext Science's value of 57.09 is 19.4% above this industry median. Based on the distribution chart, Vext Science ranks #921 out of 1045 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vext Science has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Vext Science's 9-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #921 out of 1045 companies for 9-Day RSI. This places Vext Science in the lower half of its industry. The industry median 9-Day RSI is 47.80. Vext Science's value of 57.09 is 19.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 47.80, based on 1,045 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vext Science's current 9-Day RSI of 57.09 is 19.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 47.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vext Science's current 9-Day RSI is 57.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Vext Science (FRA:VV5) has a current 9-Day RSI of 57.09. The stock's GF Value™ is €0.94, compared to a current price of €0.15 — trading 84.1% below its estimated fair value. The current 9-Day RSI is 57.09 and 19.4% above the Drug Manufacturers industry median of 47.80. Vext Science's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current 9-Day RSI is 57.09 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (FRA:VV5) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be undervalued.
The current stock price of €0.15 is trading 84.1% below its estimated GF Value™ of €0.94.
Key valuation signals for FRA:VV5:
9-Day RSI: 57.09
GF Value™: €0.94 vs. price of €0.15 (84.1% below fair value)
Industry Position: 19.4% above the Drug Manufacturers median (#921 of 1045)
No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
64GF Score
Get the complete analysis for FRA:VV5
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VV5 has been successfully added to your 
